Moleculin Biotech Inc (MBRX): That’s just above 50 so agree

S&P 500

US TECH 100

Dow Jones

Brent Oil

Bitcoin

News Focus

News Focus

Moleculin Biotech Inc (MBRX)

Keep Last Read

Next 10 Prev Next

Send PM Follow Ignore

Followers	269
Posts	30441
Boards Moderated	0
Alias Born	08/26/2015

Re: no shorts post# 1301

Tuesday, 04/23/2019 9:19:44 AM

Tuesday, April 23, 2019 9:19:44 AM

That’s just above 50 so agree

Keep Last Read

Next 10 Prev Next

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:

1D
1M
3M
6M
1Y
5Y

Detailed Quote

Recent MBRX News

Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 03/27/2026 08:01:09 PM
Moleculin Hits 45 Subject Enrollment Milestone, Triggering Final Countdown to Mid-2026 MIRACLE Trial Data Readout • GlobeNewswire Inc. • 03/23/2026 12:31:00 PM
Form 8-K - Current report • Edgar (US Regulatory) • 03/23/2026 12:30:09 PM
Form 8-K - Current report • Edgar (US Regulatory) • 03/19/2026 12:45:15 PM
Form 8-K - Current report • Edgar (US Regulatory) • 03/19/2026 12:35:12 PM
Moleculin to Present at 38th Annual ROTH Conference • GlobeNewswire Inc. • 03/17/2026 01:05:00 PM
Moleculin Releases Next CEO Corner Segment Highlighting MIRACLE Study • GlobeNewswire Inc. • 03/11/2026 01:00:00 PM
Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/09/2026 07:58:05 PM
Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 02/27/2026 07:09:49 PM
Form 8-K - Current report • Edgar (US Regulatory) • 02/20/2026 01:50:23 PM
Moleculin shares slide sharply after warrant exercise deal • IH Market News • 02/19/2026 03:46:31 PM
Moleculin Announces Exercise of Warrants for $8.3 Million Gross Proceeds • GlobeNewswire Inc. • 02/19/2026 01:39:00 PM
Form 8-K - Current report • Edgar (US Regulatory) • 02/18/2026 09:31:16 PM
Form 8-K - Current report • Edgar (US Regulatory) • 02/18/2026 01:20:16 PM
Moleculin MIRACLE Trial Delivers 40% Preliminary Blinded CRc Rate (n=30) • GlobeNewswire Inc. • 02/18/2026 01:20:00 PM
Form 8-K - Current report • Edgar (US Regulatory) • 02/17/2026 01:35:16 PM
Moleculin Announces Notice of Allowance for Japanese Patent Covering Annamycin • GlobeNewswire Inc. • 02/17/2026 01:35:00 PM
Moleculin Launches CEO Corner Platform to Share Strategic Insights • GlobeNewswire Inc. • 02/13/2026 01:32:00 PM
Form 8-K - Current report • Edgar (US Regulatory) • 02/05/2026 04:55:04 PM
Moleculin to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial • GlobeNewswire Inc. • 02/05/2026 02:15:00 PM
Form 8-K - Current report • Edgar (US Regulatory) • 01/20/2026 01:00:17 PM
Form 8-K - Current report • Edgar (US Regulatory) • 01/13/2026 01:55:12 PM
Moleculin Reports Independent Assessment Confirms No Cardiotoxicity of Annamycin in 90 Subjects • GlobeNewswire Inc. • 01/13/2026 01:55:00 PM
Form 8-K - Current report • Edgar (US Regulatory) • 01/12/2026 01:36:11 PM
Moleculin Accelerates Outlook Into 2026 With First Pivotal Trial Unblinding on Track, Global Trial Expansion, and Multiple Externally/IIT Funded Clinical Programs • GlobeNewswire Inc. • 01/12/2026 01:36:00 PM

More MBRX News

InvestorsHub community

Register for free to join our community of investors and share your ideas

You'll also get access to streaming quotes, interactive charts, trades, portfolio, live options flow